GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » NonCurrent Deferred Liabilities

Renovaro (FRA:2Q5) NonCurrent Deferred Liabilities : €2.55 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Renovaro NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Renovaro's non-current deferred liabilities for the quarter that ended in Mar. 2024 was €2.55 Mil.

Renovaro NonCurrent Deferred Liabilities Historical Data

The historical data trend for Renovaro's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro NonCurrent Deferred Liabilities Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Renovaro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 2.55

Renovaro NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Renovaro's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (FRA:2Q5) Business Description

Industry
Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines